All In Biotech

Drug Trial Radar · NCT00723502

Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients

An Open-Label, Randomized, Multicenter, Two-Arms Efficacy and Safety Study of 14 Days Treatment With Finafloxacin 400 mg b.i.d. Plus Amoxicillin 1000 mg b.i.d.Versus Finafloxacin 400 mg b.i.d. Plus Esomeprazole 40 mg b.i.d. in Patients With Helicobacter Pylori Infection

Last checked: Nov 19, 2026Latest source record: Jun 16, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 2008

Primary completion

Apr 2009

Study completion Apr 2009

Sponsor

Lead sponsor
MerLion Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Jul 28, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the H. pylori eradication rates with Finafloxacin in combination with Amoxicillin or Esomeprazole. The secondary objective is to evaluate and compare the safety and tolerability of multiple oral doses of Finafloxacin plus Amoxicillin versus Finafloxacin plus Esomeprazole.

Conditions

  • Gram-Negative Bacterial Infections
  • Helicobacter Infections
  • Dyspepsia

Interventions

  • Finafloxacin + AmoxicillinDrug

    Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration

  • Finafloxacin + EsomeprazoleDrug

    Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication of Helicobacter pyloriTime frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dr. Hein

    Marburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.